Overview

• The selected technologies target clinical note taking, cancer diagnostics, eye disease detection, hospital stay summaries and blood test interpretation.
• The seven tools are TORTUS’s clinical AI assistant, Numan’s Nu & Aegis AI Conversational & Monitoring System, Panakeia’s PANProfiler Colorectal (MSI/MMR), Octopath’s AI pathology platform, the NHS England Federated Data Platform safe summarisation tool, Eye2Gene’s AI product and DeepX Health’s DeepX AI.
• The sandbox will evaluate effectiveness, identify limitations and safety risks, and map potential pathways toward regulatory approval in a controlled setting.
• Alongside the new cohort, the MHRA published four phase-one reports detailing improvements on synthetic data validation, AI decision explainability and methods to tackle hallucinations.
• Phase two runs until March 2026 and is supported by the Regulatory Innovation Office, reflecting a government drive to equip the NHS with rigorously tested clinical AI.